RESEARCH PROGRAM · PRIORITIES & QUESTIONS
Define the question, population, gate, and stop rule together.
The order reflects which measurements later studies depend on. Each question keeps the unresolved point, population or comparator, study design, evidence that would support the claim, and evidence that would weaken it in one record.
RESEARCH PRIORITIES
3 current priorities. 3 later priorities. 11 detailed questions.
The order reflects which measurements and evidence later studies depend on.
CURRENT PRIORITIES
Build the measurements that every later study depends on.
These are proposed scientific priorities; they do not indicate that a study is active or recruiting.
- 1Question 1
Measure what each variant changes
Measure effects on RNA, protein, location in the cell, chromatin binding, and remaining function by comparing affected cells with corrected cells.
Open full question → - 2Question 3
Identify vulnerable cell types and stages
Compare the same variant in affected and corrected cells across defined cell types and stages of development.
Open full question → - 3Question 5
Follow people over time
Use shared definitions, verified records, repeated measures of meaningful function, and clear counts showing how many people were actually assessed.
Open full question →
LATER PRIORITIESConnect direct mechanism to dynamics and useful outcomes.
- 1Question 2
Separate direct effects from later effects
Connect ASH1L binding and local chromatin changes with gene activity, RNA splicing, and cell function.
Open full question → - 2Question 4
Measure response and recovery
Use a safe, defined challenge and measure the starting point, response, shutoff, recovery, repeat response, and rescue.
Open full question → - 3Question 10
Choose useful measures and outcomes
Test whether each measure is accurate, reliable, practical, sensitive to change, and meaningful to patients and families.
Open full question →
ALL ELEVEN QUESTIONS
Choose one complete research record.
Each record has its own page with the unresolved point, population, study design, support gate, and stop rule. Keeping the full records separate makes this index faster and easier to scan.
- 01DISCOVER · ALLELE
What molecular consequence does each ASH1L alteration produce?
Sequence class and protein position do not establish mechanism. For most alleles, mutant-transcript abundance, nonsense-mediated decay or escape, alternative splicing, stable protein, localization, chromatin engagement, catalytic activity, scaffolding, and residual function remain unmeasured.
Open question 01 → - 02DISCOVER · PROGRAM
Which molecular programs are shared, allele-specific, and direct?
A differentially expressed pathway can be direct, compensatory, secondary to cell-state composition, or specific to one allele or laboratory context. Bulk histone-mark abundance cannot identify the regulatory loci that matter.
Open question 02 → - 03CONFIRM · CELL STATE
Which cells and developmental states cross a dosage threshold?
Broad tissue expression does not show which human cell identities or maturation states become functionally limited by a particular allele, nor the residual dosage at which a phenotype emerges.
Open question 03 → - 04EXPLAIN · RESPONSE KINETICS
Does ASH1L dysfunction reduce challenge-and-recovery reserve?
Reduced reserve is not yet an established ASH1L mechanism. It must be defined and measured as an altered perturbation threshold, response magnitude or coordination, response termination, recovery kinetics, or re-challenge behavior—not inferred from a difficult day or one treatment-linked change.
Open question 04 → - 05CONFIRM · NATURAL HISTORY
What is the lifespan and multisystem spectrum?
The information currently shared by connected individuals and families was not collected through one standard assessment and cannot estimate prevalence. Missing information remains missing unless an adequate assessment is documented. Each comparison uses only the people whose available information can answer that question.
Open question 05 → - 06GENERALIZE · MODIFIERS
How do sex, age, and developmental transitions modify the course?
Visible differences can reflect biology, age structure, variant distribution, puberty, survival, ascertainment, documentation level, treatment exposure, or small cells. The information currently available from connected people cannot establish a sex-specific or age-specific mechanism.
Open question 06 → - 07CONFIRM · WITHIN PERSON
Which state-dependent functional changes reproduce within a person?
Parent-observed variation can be real and clinically important without identifying its cause. Apparent variable access must remain distinguishable from pain, internal discomfort, altered arousal, seizure, sleep loss, medication effect, practice, developmental fluctuation, acquired loss, and informant drift.
Open question 07 → - 08EXPLAIN · SIGNATURE
Do distinct physiological contexts precede a recurring multidomain signature?
Different contexts may converge on coordinated change across function, or they may produce unrelated symptoms. Retrospective clustering can be driven by recall, dense sampling during illness, or repeated events from one person.
Open question 08 → - 09EXPLAIN · MEDIATOR
Which measured variables are plausible temporal intermediates?
Sleep or EEG physiology, autonomic measures, pain, immune or mucosal signals, endocrine state, energy availability, intake, bowel state, medication pharmacology, and interoception are competing or interacting candidates. A one-time abnormal biomarker or parallel change is not mediation.
Open question 09 → - 10GENERALIZE · MEASUREMENT
Which biomarkers and outcomes measure meaningful change?
No biomarker is qualified to diagnose ASH1L-related disorder, track disease state, predict trajectory, or measure treatment response. A statistically responsive measure may still be unreliable, developmentally inappropriate, or unrelated to what matters to the person.
Open question 10 → - 11TRANSLATE · TARGET
Which intervention points are causally validated and trial-ready?
Cellular rescue, mouse rescue, pathway reversal, and one human response window are different evidence levels. None alone establishes a safe disease-modifying treatment, dose, developmental window, target engagement marker, or clinical benefit.
Open question 11 →